Furthermore, the finding from a phase 2, open-label clinical study (NCT02317627 at ClinicalTrials.gov) demonstrated that oral administration of KD025 reduced clinical scores in patients with psoriasis vulgaris, normalized skin pathology and down-regulated ROCK2, pSTAT3 and IRF4 levels further confirming the molecular mechanism of targeted ROCK2 inhibition20. Here, IRF4 is linked to psoriasis vulgaris.